-
Mashup Score: 1
Adding a conventional DMARD to tumor necrosis factor inhibitor therapy is not associated with clinically relevant improvements in drug retention or remission rates in people with axial spondyloarthritis, research suggests.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 2
Patients with rheumatoid arthritis may be at a greater risk for poor treatment responses if they are obese or underweight regardless of whether they are taking a tumor necrosis factor inhibitor or an alternative biologic, research indicates.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: Worse RA treatment responses seen among patients who are obese or underweight regardless of whether they are taking a #TNFinhibitor or an alternative biologic @ACR_Journals @dillirpoudel https://t.co/1Rwn5BinHj
-
-
Mashup Score: 0
Objective The coronavirus disease 2019 (COVID-19) pandemic has created multiple uncertainties regarding rheumatic diseases or their treatment, with regard to the susceptibility to or severity of the viral disease. We aimed to address these questions as they relate to spondyloarthritis (SpA). Methods We created a longitudinal survey from April 10, 2020, to April 26, 2021. There were 4723 subjects…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet-
Editor's Picks Spotlight The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment đ° https://t.co/wEN6tnBDhM đș https://t.co/jzni180VTh #ankylosingspondylitis #axialspondyloarthritis #COVID #methotrexate #sulfasalazine #TNFinhibitor
-
-
Mashup Score: 2TNF inhibitors linked to psoriasis risk in children with JIA - 2 year(s) ago
Exposure to tumor necrosis factor inhibitors is associated with a threefold increased risk for developing psoriasis in children with juvenile idiopathic arthritis, US study findings indicate.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: #TNFinhibitor use is linked to a threefold increased psoriasis risk in children with #JIA, which may be reduced with concurrent methotrexate use @ARD_BMJ https://t.co/SJywS0uCh5
-
-
Mashup Score: 1
Objective The coronavirus disease 2019 (COVID-19) pandemic has created multiple uncertainties regarding rheumatic diseases or their treatment, with regard to the susceptibility to or severity of the viral disease. We aimed to address these questions as they relate to spondyloarthritis (SpA). Methods We created a longitudinal survey from April 10, 2020, to April 26, 2021. There were 4723 subjects…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet-
Open Access The Interplay Between COVID-19 and Spondyloarthritis or Its Treatment @spondylitis đ° https://t.co/wEN6tnBDhM #ankylosingspondylitis #axialspondyloarthritis #COVID #methotrexate #sulfasalazine #TNFinhibitor https://t.co/ptitz0I856
-
-
Mashup Score: 3High BMI may adversely affect PsA treatment response - 3 year(s) ago
Response to treatment for psoriatic arthritis may be impaired for people with obesity, particularly if they are starting a TNFÂ inhibitor, research suggests.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#ACR21 news: Response to treatment for psoriatic arthritis may be impaired for people with #obesity, particularly if they are starting a #TNFinhibitor, according to research by Emily Purcell (@Penn) & colleagues https://t.co/OQOxTaGiL0
-
-
Mashup Score: 0
Study findings presented at the ACR Convergence 2021 virtual meeting support the use of TNF inhibitor therapy in patients with HIV infection.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#ACR21 news: Reassuring research from Benjamin Naovarat (@McGovernMed) for the use of #TNFinhibitor therapy in HIV-positive individuals with rheumatic conditions. Click through to read the findings https://t.co/7qO6JKkinQ
-
-
Mashup Score: 3
TNFÂ inhibitor monotherapy is associated with a lower risk for COVID-19-related hospitalization or death than other common immunomodulatory treatments given to people with immune-mediated inflammatory diseases, research suggests.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
This week's top story: Data favor #TNFinhibitor monotherapy for immune-mediated inflammatory diseases during #COVID19 pandemic â click through to read our report @rheum_covid @SecureIBD @PsoProtect @JAMANetworkOpen https://t.co/c860YalNX6
-
-
Mashup Score: 2
TNFÂ inhibitor monotherapy is associated with a lower risk for COVID-19-related hospitalization or death than other common immunomodulatory treatments given to people with immune-mediated inflammatory diseases, research suggests.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: People with IMIDs such as #RheumatoidArthritis may be less likely to be hospitalized with or die from #COVID19 if they are on #TNFinhibitor monotherapy than other common immunomodulatory treatments @JAMANetworkOpen @rheum_covid @SecureIBD @PsoProtect https://t.co/c860YaDplG
-
-
Mashup Score: 1Live attenuated zoster vaccine may be âreasonable optionâ for people taking TNF inhibitors - 3 year(s) ago
Findings from the VERVE trial suggest that the live attenuated zoster vaccine has favorable short-term immunogenicity and safety profiles in people with immune-mediated diseases treated with TNF inhibitors.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: Live attenuated zoster vaccine âmay be a reasonable optionâ for people taking a #TNFinhibitor, report @RADoctor (@UABRheum) @Dr_K @deodhara and the VERVE investigators in @AnnalsofIM https://t.co/bukghFHU06
-
News: Research by @michaelnissen et al published in @RheumJnl questions the benefit of combination therapy with a #TNFinhibitor and a conventional DMARD in people with #AxialSpondyloarthritis https://t.co/IuY7VUBzwY